What is Zacks Research’s Forecast for HALO Q1 Earnings?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Stock analysts at Zacks Research upped their Q1 2025 earnings per share (EPS) estimates for Halozyme Therapeutics in a research note issued to investors on Tuesday, January 7th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings per share of $0.98 for the quarter, up from their previous estimate of $0.97. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q4 2025 earnings at $1.33 EPS, FY2025 earnings at $4.50 EPS, Q3 2026 earnings at $1.38 EPS and Q4 2026 earnings at $1.63 EPS.

Other research analysts also recently issued research reports about the stock. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. JMP Securities raised their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. HC Wainwright reiterated a “buy” rating and issued a $68.00 price target on shares of Halozyme Therapeutics in a research note on Monday, December 30th. Finally, Piper Sandler raised their price objective on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $61.11.

Halozyme Therapeutics Trading Up 5.0 %

HALO opened at $53.76 on Thursday. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The stock has a market capitalization of $6.84 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 0.44 and a beta of 1.24. The business has a fifty day moving average price of $50.16 and a 200 day moving average price of $54.00. Halozyme Therapeutics has a 12 month low of $33.15 and a 12 month high of $65.53.

Institutional Trading of Halozyme Therapeutics

Several hedge funds have recently made changes to their positions in HALO. Congress Asset Management Co. increased its position in Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after purchasing an additional 1,988,238 shares during the period. Handelsbanken Fonder AB lifted its holdings in Halozyme Therapeutics by 76.9% in the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after acquiring an additional 856,200 shares during the period. Boston Trust Walden Corp boosted its position in shares of Halozyme Therapeutics by 54.0% during the 3rd quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock worth $39,073,000 after purchasing an additional 239,321 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Halozyme Therapeutics by 12.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock valued at $99,363,000 after purchasing an additional 209,530 shares in the last quarter. Finally, Federated Hermes Inc. lifted its stake in shares of Halozyme Therapeutics by 37.8% in the second quarter. Federated Hermes Inc. now owns 696,131 shares of the biopharmaceutical company’s stock valued at $36,449,000 after purchasing an additional 191,030 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total transaction of $532,600.00. Following the completion of the sale, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at $9,254,244.56. This trade represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.